Home › Ischemic Stroke › Oklahoma › Oklahoma City
Ischemic Stroke clinical trials in Oklahoma City, OK
4 studies for Ischemic Stroke are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Continuous Dual Aspiration Technique With Zoom System for Stroke
RecruitingObservational study
- University of Oklahoma, Health Science Center, Oklahoma City
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
RecruitingPhase 2/3
- The University of Oklahoma Health Sciences Center, Oklahoma City
About Ischemic Stroke
A stroke is a medical emergency that should be treated immediately. Read about the causes, symptoms and treatments for an ischemic stroke.
More about Ischemic Stroke on MedlinePlus
Ischemic Stroke trials in other cities
- New York City, NY18 studies
- Houston, TX18 studies
- Boston, MA17 studies
- Los Angeles, CA14 studies
- Philadelphia, PA13 studies
- Atlanta, GA13 studies
- Chicago, IL12 studies
- Baltimore, MD11 studies
- Pittsburgh, PA11 studies
- Cincinnati, OH11 studies
- St. Louis, MO11 studies
- Salt Lake City, UT10 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer15 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Pancreatic Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.